他汀类药物治疗急性肺损伤/急性呼吸窘迫综合征:基于国际数据库的系统评价与Meta分析
该系统评价与Meta分析检索PubMed/Medline、Embase、Web of Science和Cochrane Central Register of Controlled Trials至2015年11月17日,纳入5项研究(3项随机对照试验和2项观察性队列研究),共1636例ALI/ARDS患者,实验组739例接受他汀联合常规治疗,对照组897例接受常规治疗。主要终点住院死亡率在两组间无显著差异(RR=0.96,95%CI 0.79-1.15,P=0.63),亚组分析(按RCT与队列研究、不同他汀)亦无显著差异(均P>0.05)。无机械通气天数(MD=1.41,95%CI -0.32-3.13,P=0.11)、无ICU天数(MD=-0.23,95%CI -1.61-1.15,P=0.75)、ICU住院时间(MD=-1.03,95%CI -6.55-4.50,P=0.72)及ICU死亡率(RR=0.88,95%CI 0.68-1.14,P=0.33)均无显著差异。漏斗图显示住院死亡率无发表偏倚。
要点
- 纳入5项研究共1636例ALI/ARDS患者,他汀联合常规治疗组739例,常规治疗对照组897例。
- 住院死亡率两组无显著差异:RR=0.96,95%CI 0.79-1.15,P=0.63。
- 按RCT与队列研究、不同他汀的亚组分析均显示住院死亡率无显著差异(均P>0.05)。
- 无机械通气天数(MD=1.41,95%CI -0.32-3.13,P=0.11)、无ICU天数(MD=-0.23,95%CI -1.61-1.15,P=0.75)、ICU住院时间(MD=-1.03,95%CI -6.55-4.50,P=0.72)及ICU死亡率(RR=0.88,95%CI 0.68-1.14,P=0.33)均无显著差异。
- 漏斗图显示住院死亡率无发表偏倚。
适用人群与场景
- 急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)患者,纳入随机对照试验或观察性队列研究,无日期或语言限制。
研究设计与关键结果
- 研究类型为系统评价与Meta分析,纳入5项试验(3项随机对照试验和2项观察性研究),共1636例患者,实验组739例接受他汀联合常规治疗,对照组897例接受常规治疗。
- 主要终点住院死亡率两组无显著差异:RR=0.96,95%CI 0.79-1.15,P=0.63;按RCT与队列研究或不同他汀的亚组分析均无显著差异(均P>0.05)。
- 无机械通气天数MD=1.41,95%CI -0.32-3.13,P=0.11;无ICU天数MD=-0.23,95%CI -1.61-1.15,P=0.75;ICU住院时间MD=-1.03,95%CI -6.55-4.50,P=0.72;ICU死亡率RR=0.88,95%CI 0.68-1.14,P=0.33,均无显著差异。
- 漏斗图显示住院死亡率无发表偏倚。
证据类型、等级与局限
- 证据类型为系统评价与Meta分析,纳入3项随机对照试验和2项观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 系统评价与Meta分析提示,他汀可能与非ALI/ARDS患者住院死亡率、无机械通气天数、无ICU天数及ICU住院时间的显著降低无关;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To confirm the effects of statin therapy on mortality of patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS).
METHODS: PubMed/Medline, Embase, Web of Science and Cochrane Central Register of Controlled Trials were searched for articles using the terms "acute lung injury", "ALI", "acute respiratory distress syndrome", "ARDS", "statin", "simvastatin" and "rosuvastatin" updated to November 17, 2015. Randomized controlled trial (RCT) or observational cohort studies investigating the effects of statin therapy on mortality in patients with ALI or ARDS were all identified, without date or language restriction. The control group was given conventional treatment, while the experimental group was treated with statins additionally. The primary outcome was in-hospital mortality. Meanwhile, ventilator-free day, intensive care unit (ICU)-free day, ICU length of stay (LOS) and ICU mortality were also analyzed. RevMan 5.2 and STATA 13 software were used for systematic review and Meta analysis, and funnel plot was used to analyze the publication bias.
RESULTS: A total of five trials including three randomized controlled trials and two observational studies were included. Among 1 636 patients enrolled in the study, there were 739 patients in experimental group, and 897 in control group. It was shown by Meta analysis that there was no significant difference in in-hospital mortality between experimental group and control group [relative risk (RR) = 0.96, 95% confidence interval (95%CI) = 0.79-1.15, P = 0.63]. The subgroup analysis based on RCT and cohort study, or the subgroup analysis of different statins showed that there was no significant difference in in-hospital mortality between the experimental group and the control group (both P > 0.05). There were no significant differences in ventilator-free days [mean difference (MD) = 1.41, 95%CI = -0.32-3.13, P = 0.11], ICU-free days (MD = -0.23, 95%CI = -1.61-1.15, P = 0.75), ICU length of stay (MD = -1.03, 95%CI = -6.55-4.50, P = 0.72), or ICU mortality (RR = 0.88, 95%CI = 0.68-1.14, P = 0.33) between the experimental group and the control group. It was shown by funnel plot that there was no publication bias in in-hospital mortality.
CONCLUSIONS: The systematic review and meta-analysis suggests that statin may not be associated with a significant reduction in mortality, ventilator-free day, ICU-free day and ICU length of stay in patients with ALI/ARDS.
参考来源
- Chen M, Lu J, Chen Q, et al. [Statin in the treatment of ALI/ARDS: a systematic review and Meta-analysis based on international databases]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28459404. doi:10.3760/cma.j.issn.2095-4352.2017.01.011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。